Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-05-06
2008-05-06
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S317000
Reexamination Certificate
active
10840749
ABSTRACT:
The invention relates to nonadepsipeptides and process for their preparation, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases.
REFERENCES:
patent: 4754018 (1988-06-01), Tymiak et al.
patent: 2005/0075281 (2005-04-01), Von Nussbaum et al.
patent: 0196042 (1986-01-01), None
patent: 01132600 (1989-05-01), None
patent: WO2004099239 (2004-11-01), None
Tenover. Mechanisms of antimicrobial resistance in bacteria. Am Infect Control 2006. vol. 34, pp. S3-S10.
Maki et al. Katanosin B and Plusbacin A3 , Inhibitors of Peptidoglycan Synthesis in Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, Jun. 2001, pp. 1823-1827.
Palomo, C., Oiarbide, M., Ganboa, I., Miranda, J., “A concise synthesis of α-amino acid N-carboxy anhydrides of (2S, 3S)-β-substituted serines”, Tetrahedron Letts., 42: 8955-8957 (2001).
Harada, K., Suzuki, M., Kato, A., Fujii, K., Oka, H., Ito, Y., “Separation of WAP-8294A components, a novel anti-methicillin-resistantStaphylococcus aureusantibiotic, using high-speed counter-current chromatography”, J. of Chrom. A., 932 75-81 (200l).
Egner, B., Bradley, M., “Monitoring the solid phase synthesis of analogues of lysobactin and the katanosins usingin situMALDI-TOF MS”, Tetrahedron, 53(41): 14021-14030 (1997).
Tymiak, A., McCormick, T., Unger, S., “Structure determination of lysobactin, a macrocyclic peptide lactone antibiotic”, J. Org. Chem., 54: 1149-1157 (1989).
Green, D., “The bacterial cell wall as a source of antibacterial targets”, Expert Opin. Ther. Targets, 6:1-19 (2002).
Baquero, F., “Gram-positive resistance: challenge for the development of new antibiotics”, J. Antimicrob. Chemo., 39(Supp. A): 1-6 (1997).
Johnson, A., Livemore, D., Tillotson, G., “Antimicrobial susceptibility of Gram-posititve bacteria: what's current, what's anticipated?”, J. Hosp. Infect., 49(Supp. A): S3-S11 (2001).
Goldrick, B., “First reported care of VRSA in the United States”, Am. J. Nurs., 102:17 (2002).
O'Sullivan, J., McCullough J., Tymiak, A., Kirsch, D., Trejo, W., Principe, P., “Lysobactin, a novel antibacterial agent produced bylysobacter sp.”, J. Antibiot., 41: 1740-1744 (1988).
Bonner, D., O'Sullivan, J., Tanaka, S.K., Clark, J., Whitney, R., “Lysobactin, a novel antibacterial agent produced bylysobacter sp.”, J. Antibiot., 41: 1745-1751 (1988).
Shoji, J., Hinoo, H., Matsumoto, K., Hattori T., Yoshida, T., Matsurra, S., Kondo, E., “Isolaton and characterization of Katanosins A and B”, J.. Antibiot, 41(6): 713-718 (1988).
Anlauf Sonja
Bruening Michael-Alexander
Brunner Nina
Endermann Rainer
Fürstner Chantal
AiCuris GmbH & Co. KG
Cordero Garcia Marcela M
Morrison & Foerster / LLP
Tsang Cecilia J.
LandOfFree
Acylated nonadepsipeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Acylated nonadepsipeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acylated nonadepsipeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3941127